PhoenixBio (6190) · FactFirst statedLatest Changes in Directors and Officers (2026-05-15): "Reframed"
Appointment of Director Kaguni Masakazu (加国雅和) as President of KMT Hepatech, Inc.
First written in FY2021-Q3. 1 of 2 entries say "Reframed", first in 2026-05-15. Latest entry: 2026-05-15.
2entries
6years
1from disclosures
How it moved
Same theme, other companies
Director's appointment as subsidiary president and concurrent holding of both positionsA theme 1 companies write about · 0 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-05-15ReframedChanges in Directors and Officers
「Kaguni Masakazu (加國 雅和) Representative Director and President Director」
For Kaguni Masakazu (加國 雅和), the disclosure indicates that he is scheduled to become Representative Director and President on 26 June 2026, whereas the previous disclosure described his appointment as President of KMT Hepatech, Inc. The formal decision is scheduled to be made at the Ordinary General Meeting of Shareholders and the subsequent Board of Directors meeting to be held on that date. - FY2021-Q3First statedAnnual report
「Director and KMT Hepatech,Inc. President Director Head of Contract Testing Division Masakazu Kaguni (加国 雅和) 1 December 2020」
Effective 1 December 2020, Masakazu Kaguni (加国 雅和)'s position changed from Director and Head of Contract Testing Division to Director and President of KMT Hepatech,Inc.